Top

Published in:

01-02-2016 | AdisInsight Report

Daratumumab: First Global Approval

Author: Kate McKeage

Published in: Drugs | Issue 2/2016

Abstract

Daratumumab (Darzalex™) is a first-in-class, humanized IgG1κ monoclonal antibody that targets the CD38 epitope and was developed by Janssen Biotech and Genmab. Intravenous daratumumab was recently approved via an accelerated approval programme in the USA for patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent. The drug is in preregistration for this indication in the EU and Canada. In a phase II trial in patients with previously treated (as described above) relapsed or refractory multiple myeloma, monotherapy with daratumumab 16 mg/kg achieved an overall response rate of approximately 30 %. This article summarizes the milestones in the development of daratumumab leading to this first approval for multiple myeloma.

Janssen Biotech Inc. Darzalex™ (daratumumab): prescribing information. 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761036s000lbl.pdf. Accessed 17 Dec 2015.

Genmab AS. Genmab enters worldwide agreement with Janssen for daratumumab [media release]. http://ir.genmab.com/releasedetail.cfm?ReleaseID=703394. Accessed 17 Dec 2015.

Phipps C, Chen Y, Gopalakrishnan S, et al. Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development. Ther Adv Hematol. 2015;6(3):120–7.PubMedCentralCrossRefPubMed

de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840–8.CrossRefPubMed

US Food and Drugs Administration. FDA approves Darzalex for patients with previously treated multiple myeloma. 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472875.htm. Accessed 17 Dec 2015.

Janssen. Daratumumab receives breakthrough therapy designation in double refractory multiple myeloma from US Food and Drug Administration [media release]. http://www.investor.jnj.com/releasedetail.cfm?releaseid=761001. Accessed 17 Dec 2015.

Genmab. Genmab Announces US FDA approval of Darzalex™ (daratumumab) for multiple myeloma and updates financial guidance [media release]. http://ir.genmab.com/releasedetail.cfm?ReleaseID=942957. Accessed 17 Dec 2015.

Genmab. US FDA grants priority review for daratumumab for double refractory multiple myeloma [media release]. http://ir.genmab.com/releasedetail.cfm?ReleaseID=930345. Accessed 17 Dec 2015.

Janssen. Janssen submits marketing authorization application for daratumumab for European patients with heavily pretreated multiple myeloma [media release]. http://www.janssen.com/emea/sites/www_janssen_com_emea/files/dara_eu_filing_press_release_final.pdf. Accessed 17 Dec 2015.

10.

Janssen. Janssen’s new drug submission for daratumumab for treatment of multiple myeloma accepted for review by Health Canada [media release]. https://www.janssen.com/canada/sites/www_janssen_com_canada/files/daratumumab_filing_news_release.pdf. Accessed 17 Dec 2015.

11.

Matas-Cespedes A, Vidal-Crespo A, Rodriguez V, et al. Daratumumab, a novel anti-CD38 monoclonal antibody shows anti-tumor activity in CLL and hampers leukemia-microenvironment interactions [abstract]. Blood. 2014;124:4680.

12.

Halozyme Therapeutics. Halozyme Therapeutics enters a global collaboration with Janssen to develop and commercialize subcutaneous products using ENHANZE™ technology [media release]. http://www.halozyme.com/. Accessed 17 Dec 2014.

13.

Overdijk MB, Verploegen S, Bogels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. mAbs. 2015;7(2):311–21.CrossRefPubMed

14.

Krejcik J, Casneuf T, Nijhof I, et al. Immunomodulatory effects and adaptive immune response to daratumumab in multiple myeloma [abstract]. Blood. 2015;126:3037.

15.

van der Veer MS, de Weers M, van Kessel B, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica. 2011;96(2):284–90.PubMedCentralCrossRefPubMed

16.

Nijhof IS, Groen RWJ, Noort WA, et al. Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin Cancer Res. 2015;21(12):2802–10.CrossRefPubMed

17.

Nijhof IS, Lammerts van Bueren JJ, van Kessel B, et al. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015;100(2):263–8.CrossRefPubMed

18.

Nijhof IS, Groen RW, Lokhorst HM, et al. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia. 2015;29(10):2039–49.CrossRefPubMed

19.

Chaulagain CP, Ma X, Doshi P, et al. Pre-clinical translational studies of daratumumab in patients with myeloma or AL amyloidosis undergoing autologous hematopoietic stem cell transplantation (SCT) [abstract no. 8587]. J Clin Oncol. 2015;33(15 Suppl 1).

20.

Doshi P, Sasser AK, Axel A, et al. Daratumumab treatment in combination with CHOP or R-CHOP results in the inhibition or regression of tumors in preclinical models of non-hodgkins lymphoma [abstract no. P434]. Haematologica. 2014;99(Suppl 1):138–9.

21.

Clemens PL, Yan X, Puchalski T, et al. Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma (MM) after prior proteasome inhibitor (PI) and immunomodulatory drug (IMiD) treatment [abstract no. PO-333]. In: 15th International Myeloma Workshop; 2015.

22.

Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207–19.CrossRefPubMed

23.

Lonial S, Weiss B, Usmani S, et al. Phase 2 study of daratumumab monotherapy in patients with >3 lines of prior therapy or double refractory multiple myeloma: 54767414MMY2002 (SIRIUS) [abstract no. S430]. Haematologica. 2015;100(Suppl 1):153.

24.

Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015;55:1545–54.CrossRefPubMed

25.

Plesner T, Arkenau HT, Gimsing P, et al. Daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: updated results of a phase 1/2 study (GEN503) [abstract]. Blood. 2015;126:507.

Title: Daratumumab: First Global Approval
Author: Kate McKeage
Publication date: 01-02-2016
Publisher: Springer International Publishing
Published in: Drugs / Issue 2/2016
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-015-0536-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Daratumumab: First Global Approval

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

An Update on Medical Treatment Options for Hidradenitis Suppurativa

Asfotase Alfa: A Review in Paediatric-Onset Hypophosphatasia

Therapies to Preserve β-Cell Function in Type 1 Diabetes

Diagnosis and Management of Systemic Sclerosis: A Practical Approach

Dimethyl Fumarate: A Review in Relapsing-Remitting MS

Necitumumab: First Global Approval